UTICORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UTICORT (UTICORT).
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4; metabolites are glucuronidated and excreted renally. |
| Excretion | Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation. |
| Half-life | Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment. |
| Protein binding | 90-95% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% (first-pass effect); topical: 2-5% (systemic absorption dependent on skin integrity); intravenous: 100%. |
| Onset of Action | Topical: within 2-3 hours; oral: 30-60 minutes; intravenous: within 5 minutes. |
| Duration of Action | Topical: 12-24 hours with once-daily application; oral: 6-12 hours; intravenous: 4-8 hours. |
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for renal impairment. No GFR-based data available. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B/C: Use with caution due to potential for systemic accumulation; limit to small areas and short duration. |
| Pediatric use | Children ≥2 years: Apply sparingly to affected area once or twice daily for ≤2 weeks. Avoid occlusion. Not for diaper dermatitis. |
| Geriatric use | Use with caution due to thinner skin and increased risk of systemic absorption and skin atrophy. Apply sparingly to limited areas for shortest duration possible. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for UTICORT (UTICORT).
| Breastfeeding | Betamethasone is excreted in breast milk in small amounts. M/P ratio: ~0.4. At maternal doses ≤15 mg/day, infant exposure is minimal and unlikely to cause adrenal suppression. Monitor infant for growth and development if prolonged high-dose therapy. |
| Teratogenic Risk | Uticort (betamethasone) is a corticosteroid. First trimester: Increased risk of cleft palate (odds ratio ~3.4). Second/third trimester: Prolonged use may cause fetal adrenal suppression, intrauterine growth restriction (IUGR), and preterm birth. Risk-benefit must be weighed. |
■ FDA Black Box Warning
Do not use for primary treatment of bacterial, fungal, viral, or parasitic infections without appropriate antimicrobial therapy. Systemic absorption may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency after withdrawal.
| Serious Effects |
["Hypersensitivity to betamethasone or any component","Untreated bacterial, fungal, viral, or parasitic infections at application site"]
| Precautions | ["HPA axis suppression, especially with prolonged use or large body surface area application","Cushing's syndrome with systemic absorption","Local adverse reactions including atrophy, striae, and telangiectasia","Increased risk of infection","Allergic contact dermatitis","Ophthalmic effects if used near eyes"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, blood glucose (especially in diabetic patients), and signs of infection. Fetal monitoring: serial ultrasound for growth restriction if prolonged use. Neonatal monitoring for adrenal insufficiency if betamethasone administered near term. |
| Fertility Effects | Animal studies show reduced fertility at high doses. Human data limited: may cause menstrual irregularities, but no definitive evidence of impaired fertility. Use with caution in women attempting pregnancy. |